ED/VP Medical Science & Strategy – Oncology, China Asset Evaluation and Global Development (Mandarin Proficiency)

Work Schedule

Standard (Mon-Fri)

Environmental Conditions

Office

Job Description

At Thermo Fisher Scientific, you’ll discover meaningful work that makes a positive impact on a global scale. Join our colleagues in bringing our Mission to life – enabling our customers to make the world healthier, cleaner and safer. We provide our teams with the resources needed to achieve individual career goals while taking science a step beyond through research, development and delivery of life-changing therapies. With clinical trials conducted in more than 100 countries and ongoing development of novel frameworks for clinical research through our PPD clinical research portfolio, our work spans laboratory, digital and decentralized clinical trial services. Your determination to deliver quality and accuracy will improve health outcomes that people and communities depend on – now and in the future.

• Must be legally authorized to work in the United States or Canada without sponsorship.

• Must be able to pass a comprehensive background check, which includes a drug screening (where applicable).

• Must be able to work with regular overlap to support China working hours.

Position Summary:

Thermo Fisher Scientific is seeking a physician with extensive oncology clinical development experience to join a cross-functional team that identifies, evaluates, and partners with biotechnology companies and academic laboratories in China that are developing novel oncology therapeutics. Many of these programs generate promising preclinical and early-phase clinical data in China but have not yet established the regulatory, operational, and strategic foundation required to advance into multiregional trials and global registration.

The incumbent will evaluate preclinical and clinical-stage oncology assets, assess which are most likely to succeed in global development, and help shape partnerships through which Thermo Fisher Scientific and its PPD clinical research business support these assets in their transition from early-phase trials in China to global pivotal trials and registration with regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As a member of a larger diligence team, the incumbent will provide the medical and scientific judgment that underpins strategic recommendations to Thermo Fisher Scientific senior leadership as to which assets and companies should be prioritized and which should be deprioritized. The position requires proven ability to drive both strategic and measurable business outcomes. The incumbent’s oncology track record and expertise must be extensive enough to ensure recognition as a peer of senior medical and scientific leaders in the pharmaceutical and biotechnology industries.

Key Responsibilities:

1. Asset Identification and Scientific Due Diligence

• Identify and screen preclinical and clinical-stage oncology assets originating from biotechnology companies, academic laboratories, and research hospitals in China, drawing on scientific literature, conference presentations, regulatory and trial registry records, and direct engagement with sponsors and investigators.

• Evaluate the scientific foundation of each asset, including mechanism of action, target validation, biological rationale, preclinical pharmacology and toxicology, and translational and biomarker strategy.

• Assess differentiation relative to current standard of care and to competing assets in development globally, across modalities including antibody–drug conjugates, bispecific antibodies, cell and gene therapies, and targeted small molecules.

• Critically appraise early-phase clinical data generated in China, including dose-escalation design, dose selection and optimization, safety and tolerability, pharmacokinetics, and preliminary efficacy, with attention to study design quality, endpoint selection, data integrity, and Good Clinical Practice (GCP) compliance.

• Assess the likely applicability of China-generated clinical data to global regulatory submissions, taking into account differences in standard of care, patient populations, and trial conduct, with reference to International Council for Harmonisation (ICH) guidelines E5 (ethnic factors in the acceptability of foreign clinical data) and E17 (multiregional clinical trials) and to FDA regulations and guidance on the use of foreign clinical data.

• Define the remaining path to global registration for each asset, including indication and line-of-therapy selection, likely regulatory expectations in the United States, European Union, and other major markets, and the principal clinical, regulatory, and technical risks.

• Collaborate with functional experts to assess nonclinical package completeness and chemistry, manufacturing, and controls (CMC) readiness for global development.

2. Strategic Recommendations and Portfolio Prioritization

• Synthesize scientific, clinical, regulatory, and commercial findings into clear, evidence-based recommendations on whether each asset and company should be prioritized, monitored, or deprioritized.

• Contribute to the development and consistent application of a structured evaluation framework and scoring criteria that allow assets to be compared across modalities, tumor types, and stages of development.

• Prepare and present diligence findings and recommendations to Thermo Fisher Scientific senior leadership and governance forums, communicating complex scientific information concisely to executive audiences.

• Monitor the oncology innovation landscape in China, the cross-border licensing and partnering environment, and relevant regulatory and policy developments in the United States and China, and advise leadership on their implications for portfolio strategy.

3. Partnership Development and Global Development Strategy

• Engage peer-to-peer, in Mandarin and English, with chief medical officers, chief scientific officers, founders, and principal investigators of biotechnology companies and academic laboratories in China to build trusted relationships and support partnership discussions.

• Develop global clinical development plans for partnered assets that bridge early-phase data from China to multiregional clinical trials (MRCTs), including dose-optimization strategy, indication sequencing, registrational trial design, and endpoint selection.

• Advise partners on global regulatory strategy, including preparation for Investigational New Drug (IND) applications, pre-IND and end-of-phase meetings with FDA, scientific advice procedures with EMA, and integration of data generated under the oversight of China’s National Medical Products Administration (NMPA) into global submissions.

• Through the PPD consulting practice, provide industry-leading product development plans and top-level design of the clinical trial protocols required by those plans.

• Support proposals, bid defenses, and client governance and advisory boards for partnered programs, including interactions with partner physicians and indication leaders.

• Author and review Investigator’s Brochures, clinical study reports, regulatory briefing documents, and clinical sections of New Drug Applications (NDAs), Biologics License Applications (BLAs), and Marketing Authorization Applications (MAAs).

4. Cross-Functional Collaboration and Internal Expertise

• Work within a multidisciplinary diligence team that includes business development, corporate strategy, regulatory affairs, clinical operations, biostatistics, and commercial colleagues, ensuring that medical and scientific perspectives are fully integrated into recommendations.

• Liaise with investigators and key opinion leaders (KOLs) in China, the United States, and Europe to inform asset assessments and trial feasibility.

• Contribute to the design and reporting of feasibility assessments for global trials of partnered assets.

• Provide indication-specific training and guidance to internal clinical teams, and mentor and supervise clinical scientists.

• Participate in multidisciplinary working groups and initiatives that strengthen Thermo Fisher Scientific’s capabilities in supporting cross-border oncology development.

Minimum Qualifications:

• Doctor of Medicine (MD) or equivalent required.

• Board certification, or equivalent, in medical oncology, hematology and oncology, or a closely related specialty.

• At least five years of experience in the pharmaceutical or biotechnology industry leading oncology clinical development, including leadership of at least one asset from discovery through registration.

• Demonstrated experience evaluating early-phase oncology data and making development or portfolio recommendations.

• Proficiency in spoken and written English and Mandarin Chinese.

• Active medical license preferred but not required.

Preferred Qualifications:

• Direct experience with oncology programs originating in China, including clinical development under NMPA oversight or the transition of China-originated assets into global development.

• Experience conducting scientific due diligence for in-licensing, partnering, or investment decisions in a pharmaceutical business development, venture capital, or corporate strategy setting.

• Experience designing or leading MRCTs, and familiarity with the FDA Oncology Center of Excellence’s Project Optimus dose-optimization initiative and with FDA and EMA expectations for global registration.

• An established professional network among oncology investigators, biotechnology leaders, and academic institutions in China.

• Experience presenting to executive leadership teams, boards, or investment committees.

Knowledge, Skills and Abilities:

• Rigorous, independent scientific judgment, with the ability to reach clear and defensible conclusions from incomplete or heterogeneous data.

• Able to work effectively in a matrix organization.

• Able to demonstrate the following key high-performance behaviors: decisive, customer driven, flexible thinking, smart risk-taking, and continuous improvement.

• Leads, influences, and motivates staff within and across departments.

• Strong in presenting and communicating complex information clearly to scientific and executive audiences.

• Able to work effectively across Chinese and Western business and scientific cultures.

• Able to handle sensitive and confidential information, including nonpublic data from prospective partners, with discretion.

• Possesses a “can do” attitude and is capable of implementing and following through on activities and projects.

• Flexibility to travel domestically and internationally, including periodic travel to China.

What We Offer:

• Full-time position

• Base salary plus a competitive bonus, equity, and benefits package

• Exposure to a broad portfolio of novel oncology assets across modalities and stages of development

• The opportunity to contribute to a strategic Thermo Fisher Scientific initiative supporting the global development of oncology innovation originating in China

Compensation

The estimated annualized pay range for this position in Oregon is $300,000.00–$400,000.00.